The Investment Thesis Update
Gemphire (GEMP) is a small cap ($15M) clinical stage biopharmaceutical company focused on the clinical development of therapies for cardiometabolic disorders, including dyslipidemia and NASH. Gemcabene (CI-1027 or PD 72953) was in clinical development as a lipid altering agent prior to it being licensed from Pfizer in 2011. Gemcabene is promoted as a first in class investigative drug candidate with pleiotropic mechanisms that positively regulates dyslipidemia (i.e. hypercholesterolemia, hypertriglyceridemia) and potentially NAFLD/NASH. Gemphire on the pleiotropic mechanism of action of gemcabene (see below):
At a high level, gemcabene acts